Search More Than 6,000,000 Posts
Results 1 to 4 of 4
  1. #1
    Mike.B is offline New Member
    Join Date
    Mar 2002

    Dinistenile What is it?

    Can someone tell me what this is, and does?
    Denistenile. (from Spain)
    Dihidroepiandrosterona. DCI.
    6 brown amps to a box filled with powder
    6 bottles 3ml water solution to mix.

  2. #2
    Mike.B is offline New Member
    Join Date
    Mar 2002
    Sorry, that's 2 bottles of water solution!
    AND white powder in the amps, like HGH!

  3. #3
    jbrand's Avatar
    jbrand is offline Member
    Join Date
    Apr 2002
    new york

    Re: Dinistenile What is it?

    Originally posted by Mike.B
    Can someone tell me what this is, and does?
    Denistenile. (from Spain)
    Dihidroepiandrosterona. DCI.
    6 brown amps to a box filled with powder
    6 bottles 3ml water solution to mix.
    Sounds like DHEA to me, the chemical that is. Why they are in vials with water is beyond me.
    Last edited by jbrand; 04-14-2002 at 10:49 PM.

  4. #4
    gymnut4u's Avatar
    gymnut4u is offline Member
    Join Date
    Jan 2002
    north carloina

    hope this helps !

    Taken from med text !

    Dehydroepiandrosterone (DHEA) is a metabolite on the steroidogenic
    pathway between cholesterol and the sex steroids . In the human and
    other primates, the adrenal is the most prolific source of DHEA, with
    the sulfated derivative, DHEAS, synthesized primarily in hepatic and
    adrenal tissues. (For the remainder of this Announcement, the
    abbreviation DHEA refers to DHEA and/or DHEA sulfate collectively.)
    In primates, DHEA is present in levels considerably higher than the
    other steroid metabolites of cholesterol. Many cross-sectional
    studies have documented that serum DHEA levels in humans and other
    primates is developmentally regulated, i.e., DHEA increases during
    pregnancy to a high level prior to birth, drops precipitously at
    birth, increases at adrenarche to a maximum around the early 20's,
    then declines gradually into old age (while other major adrenal
    steroids, glucocorticoids, remain relatively unchanged with age),
    reaching about 10-20% of its peak value around age 80.

    Clinical and epidemiologic studies on the relationship of DHEA levels
    to diseases and other health outcomes have not had consistent
    results. Some prospective studies have found an inverse relationship
    between DHEA levels and risk for cardiovascular disease risk in men,
    while others have found no relationship. A case-control study found
    low DHEA levels in Alzheimer's disease patients relative to
    age-matched controls, while another did not. Other cross-sectional
    studies have reported associations between low DHEA levels and
    dyspnea, depressive symptoms, impairments in activities of daily
    living in older women (but not men), elevated mortality risk in older
    men (but not women), and rheumatoid arthritis, but there have not
    been reports of studies to replicate these findings. On the other
    hand, a case-control study found higher DHEA levels in cases of
    ovarian cancer relative to controls, and two studies found an
    association between high DHEA levels and hypertension, while others
    found no relationship. Most of these studies had very limited power
    to address the potential confounding effects of covariates which
    could contribute to spurious associations (or lack of association)
    between DHEA levels and the outcomes reported.

    Animal studies, generally performed in species in which endogenous
    DHEA levels are normally relatively low and may not change
    substantially with age, and involving dietary DHEA at very high
    levels for most studies, show delayed tumor formation, prevention of
    atherosclerosis, weight loss in obese animals and, in general,
    retardation of the development of many chronic age-related pathologic

    The conference "Dehydroepiandrosterone (DHEA) and Aging", supported
    in part by the NIH and sponsored by the New York Academy of Sciences,
    was held in Washington, DC in June, 1995 (Bellino, FL, Daynes, RA,
    Hornsby, PJ, Lavrin, DH and Nestler, JE, eds. Annals of the New York
    Academy of Sciences, vol 774, New York, 1995). The purpose of the
    conference was to define a future research agenda based on a review
    of the current status of a variety of ongoing investigations into a)
    mechanisms of the apparent steady decline of DHEA with age from the
    mid-twenties to old age, b) epidemiologic studies suggesting positive
    health benefits for individuals with higher levels of DHEA for their
    age group and clinical studies of effects in individuals supplemented
    with DHEA in the short-term studies, and c) health effects of
    supplementary DHEA in animal studies.

Thread Information

Users Browsing this Thread

There are currently 1 users browsing this thread. (0 members and 1 guests)

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts